XML 81 R48.htm IDEA: XBRL DOCUMENT v3.25.0.1
License and Collaboration Arrangements (Additional Information) (Details) - USD ($)
$ in Thousands
 4 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Oct. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License revenue   $ (358,711) $ (310,463) $ (331,339)  
Accounts receivable   20,392 14,454    
Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Future potential milestone payment receivable   109,500      
XACDURO          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License revenue   (21,070) (2,003) 0  
Royalty revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License revenue   (241,733) (238,846) (311,645)  
GIAPREZA          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License revenue   (55,037) (41,294) (14,214)  
License and other revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License revenue   (19,486) (11,000) 0  
XERAVA          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License revenue   $ (21,385) (17,320) $ (5,480)  
Percentage of royalty payable on net sales   2.25%      
Zai Lab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Business combination deferred consideration   $ 5,300      
Zai Lab | Amended Zai Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License and other revenue   8,100      
Accounts receivable   1,600      
Zai Lab | Interim Supply Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Accounts receivable   600      
Amount on net product sales recognized   6,300      
Zai Lab | Manufacturing Stage Transfer Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License and other revenue   3,400      
Accounts receivable   100      
Zai Lab | Sulbactam Durlobactam          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License revenue recognized   8,000      
Zai Lab | XACDURO          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License revenue recognized     3,000    
Zai Lab | XACDURO | Regulatory Starting Material          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Letter agreement for purchase of material used for production value         $ 10,900
Zai Lab | Research and Development Support | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Future potential milestone payment receivable   91,000      
PAION AG | Royalty revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues $ 0 $ 1,500 0    
PAION AG | Cost Reimbursement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues     1,300    
Everest Medicines Limited          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Royalties payable period after first commercial sale of product   10 years      
Everest Medicines Limited | Commercial Supply Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues 800 $ 3,200 $ 2,400    
Percentage of reimbursed for direct and certain indirect manufacturing costs     110.00%    
Everest Medicines Limited | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales milestone payments receivable     $ 20,000    
Everest Medicines Limited | Royalty revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues 0 4,700 1,400    
Everest Medicines Limited | License and other revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues     8,000    
Basilea          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Upfront payment under intangible asset   4,000      
George Washington University | GIAPREZA          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Obligation to pay royalties 0 $ 3,400 2,500    
Percentage of royalty payable on net sales   6.00%      
Percentage of royalty on payments received from sublicensees   15.00%      
Harvard University          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of license revenue   $ 1,400 1,200    
Percentage of royalty payable on net sales   5.00%      
Percentage of royalty on payments received from sublicensees   20.00%      
Percentage of minimum royalty rate   4.50%      
Percentage of maximum royalty based on achievement of annual net product sales thresholds   7.50%      
Harvard University | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Clinical development and regulatory milestones amount payable   $ 15,100      
Harvard University | Royalty revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues $ 0 $ 0 0    
Paratek Pharmaceuticals, Inc | XERAVA          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Claim Expiration Date   2023-10      
AstraZeneca | Durlobactam          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Subscription agreement one-time milestone payment on net sales   $ 5,000      
Term of the milestone payment on net sales   3 months      
RoyaltyExpense   $ 0 $ 0    
AstraZeneca | Zoliflodacin          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Subscription agreement one-time milestone payment on first commercial sale   $ 10,000      
Term of the milestone payment on first commercial sale   2 years